REG - N4 Pharma PLC - Patent filing update

N4 PharmaAnnouncement

01/11/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221101:nRSA8091Ea&default-theme=true

RNS Number : 8091E  N4 Pharma PLC  01 November 2022

01 November 2022

N4 Pharma Plc

("N4 Pharma" or the "Company")

Patent filing update

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing
Nuvec®, a novel delivery system for cancer treatments and vaccines, provides
an update on its patent application for Nuvec®, filed in March 2020 (no.
PCT/GB2021/050960 Gene Therapy Vectors).

The Company originally filed a Patent Cooperation Treaty ("PCT") patent
application for Nuvec® to be used to manufacture viral vectors and to make
viral vectors more efficient in applications such as ex-vivo gene therapy
treatments. Under the terms of the PCT application process and following
feedback from an international patent search, the Company is now making
enhancements to the claims of the applications in the territories in which it
wishes to gain patent protection. N4 pharma is pursuing this patent
application which, if granted, would be in addition to the patents it has
exclusively licensed from the University of Queensland.

The Company has decided to focus its claims on the use of the specific spiky
properties of Nuvec™ to load and transfect viral vectors, especially
adenoviral vectors and lentiviral vectors. This is based on feedback from the
examiner and further work the Company has done that has shown how combining
Nuvec® with adenoviral vectors (in addition to its earlier work on lentiviral
vectors) can lead to an improvement in vector performance and a reduction in
the amount of the viral vector needed.

The Company has filed ongoing patent applications in the following
territories: Europe (including UK); USA; Japan; India and Canada. It will also
file applications in Australia and China in due course.

 

Nigel Theobald, Chief Executive Officer of the Company, commented:

"We are seeking to refine our claims to give this patent the greatest chance
of being granted in a field with strong commercial opportunity. Should the
patent be granted in these territories it would mirror the regions granted for
the main patent which the Company has licensed from the University of
Queensland and further strengthen the commercial protection of Nuvec®."

 

Enquiries:

 N4 Pharma Plc                                       Via IFC Advisory

 Nigel Theobald, CEO

 Luke Cairns, Executive Director
 SP Angel Corporate Finance LLP                      Tel: +44 (0)20 3470 0470

 Nominated Adviser and Joint Broker

 Matthew Johnson/Caroline Rowe (Corporate Finance)

 Vadim Alexandre/Rob Rees (Corporate Broking)
 IFC Advisory Limited                                Tel: +44 (0)20 3934 6630

 Financial PR

 Graham Herring

 Zach Cohen

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery
system for cancer and vaccine treatments using its unique silica nanoparticle
delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel
antigens for cancer and vaccine treatments to use Nuvec® as the delivery
vehicle to get their antigen into cells to express the protein needed for the
required immunity. As these products progress through pre clinical and
clinical programs, N4 Pharma will seek to receive up front payments, milestone
payments and ultimately royalty payments once products reach the market.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFDDFWFEESEIS